Homology discloses lawsuit and demand letters challenging Q32 merger; provides supplemental proxy disclosures

Q32 Bio Inc.

Stockholder Kevin Welsh filed a putative class action on Feb 22, 2024 under Sections 14(a) and 20(a) alleging material omissions in the merger proxy statement.
Twelve other purported stockholders sent demand letters with similar allegations regarding the proxy statement.
Company denies all allegations and believes proxy complies with law, but voluntarily supplements disclosures to moot claims without admitting liability.
Supplemental disclosures include additional details on TD Cowen's DCF analysis: perpetuity growth rate of (33)%, probability of success 15%-30%, discount rates 14%-17%.
Separate 2022 securities class action (Pizzuto) remains pending; oral argument on motion to dismiss held March 4, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.